iSpecimen Statistics
Total Valuation
iSpecimen has a market cap or net worth of $4.00 million. The enterprise value is -$2.61 million.
Important Dates
The next estimated earnings date is Monday, May 18, 2026, after market close.
| Earnings Date | May 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
iSpecimen has 741,556 shares outstanding. The number of shares has increased by 547.47% in one year.
| Current Share Class | 741,556 |
| Shares Outstanding | 741,556 |
| Shares Change (YoY) | +547.47% |
| Shares Change (QoQ) | +32.06% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 0.57% |
| Float | 741,551 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.08 |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/TBV Ratio | 4.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.09.
| Current Ratio | 1.12 |
| Quick Ratio | 1.11 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -905.21 |
Financial Efficiency
Return on equity (ROE) is -327.77% and return on invested capital (ROIC) is -160.77%.
| Return on Equity (ROE) | -327.77% |
| Return on Assets (ROA) | -59.44% |
| Return on Invested Capital (ROIC) | -160.77% |
| Return on Capital Employed (ROCE) | -272.05% |
| Weighted Average Cost of Capital (WACC) | 14.37% |
| Revenue Per Employee | $275,571 |
| Profits Per Employee | -$1.50M |
| Employee Count | 7 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.20% in the last 52 weeks. The beta is 1.98, so iSpecimen's price volatility has been higher than the market average.
| Beta (5Y) | 1.98 |
| 52-Week Price Change | -89.20% |
| 50-Day Moving Average | 7.15 |
| 200-Day Moving Average | 24.69 |
| Relative Strength Index (RSI) | 46.20 |
| Average Volume (20 Days) | 2,207,866 |
Short Selling Information
| Short Interest | 5.53M |
| Short Previous Month | 580,752 |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.19 |
Income Statement
In the last 12 months, iSpecimen had revenue of $1.93 million and -$10.49 million in losses. Loss per share was -$91.15.
| Revenue | 1.93M |
| Gross Profit | 24,110 |
| Operating Income | -8.98M |
| Pretax Income | -10.49M |
| Net Income | -10.49M |
| EBITDA | -8.72M |
| EBIT | -8.98M |
| Loss Per Share | -$91.15 |
Full Income StatementBalance Sheet
The company has $6.88 million in cash and $268,798 in debt, with a net cash position of $6.61 million or $8.92 per share.
| Cash & Cash Equivalents | 6.88M |
| Total Debt | 268,798 |
| Net Cash | 6.61M |
| Net Cash Per Share | $8.92 |
| Equity (Book Value) | 3.09M |
| Book Value Per Share | 14.57 |
| Working Capital | 723,284 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.24 million and capital expenditures -$454, giving a free cash flow of -$4.24 million.
| Operating Cash Flow | -4.24M |
| Capital Expenditures | -454 |
| Depreciation & Amortization | 260,029 |
| Net Borrowing | n/a |
| Free Cash Flow | -4.24M |
| FCF Per Share | -$5.72 |
Full Cash Flow StatementMargins
| Gross Margin | 1.25% |
| Operating Margin | -465.42% |
| Pretax Margin | -543.68% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
iSpecimen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -547.47% |
| Shareholder Yield | -547.47% |
| Earnings Yield | -261.90% |
| FCF Yield | -105.91% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 28, 2026. It was a reverse split with a ratio of 1:40.
| Last Split Date | Apr 28, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
iSpecimen has an Altman Z-Score of -14.56 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.56 |
| Piotroski F-Score | 2 |
